Glenmark gets USFDA nod for skin treatment cream

By: | Published: August 8, 2016 2:52 PM

Glenmark Pharmaceuticals has received final nod from the US health regulator for generic Triamcinolone acetonide cream used for reducing itching ,redness and swelling on skin.

Company’s current portfolio consists of 108 products authorised for distribution in the US marketplace and 61 abbreviated new drug applications (ANDA’s) pending approval with the USFDA, it added. (Source: Reuters)

Glenmark Pharmaceuticals has received final nod from the US health regulator for generic Triamcinolone acetonide cream used for reducing itching ,redness and swelling on skin.

Company’s US subsidiary “Glenmark Pharmaceuticals Inc has been granted final approval by the United States Food and Drug Administration (USFDA) for Triamcinolone acetonide cream $, 0.1 per cent,” Glenmark said in a BSE filing.

The product is generic version of Delcor Asset Corporation’s Kenalog cream in the same strength, it added.

According to IMS Health sales data for the 12-month period ended June 2016, the Kenalog cream, 0.1 per cent market (includes brand and all available therapeutic equivalents) achieved annual sales of approximately $43.6 million, Glenmark said.

Company’s current portfolio consists of 108 products authorised for distribution in the US marketplace and 61
abbreviated new drug applications (ANDA’s) pending approval with the USFDA, it added.

Shares of Glenmark Pharmaceuticals were trading 1.32 per cent up at Rs 854.00 on BSE.

 

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition